Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature

Background Fasting insulin modulates growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) synthesis, but its relation to early height response to recombinant human GH (rhGH) therapy is unclear. We examined this in children with idiopathic short stature (ISS). Methods This single-center retrospective cohort study reviewed records of children aged 3–14 years who started rhGH monotherapy for ISS at a tertiary pediatric endocrinology center between December 2018 and December 2024. Children with another identifiable cause of short stature, obesity, diabetes, uncontrolled hypothyroidism, Turner syndrome or concurrent gonadotropin-releasing hormone agonist therapy were excluded. The primary outcome was the change in height standard deviation score (SDS) from baseline to 3 months, and the secondary outcomes were the 3-month height gain and the change in height SDS from baseline to 6 months. Baseline fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) were related to the outcomes by Spearman correlation and by linear regression adjusted for age, sex, baseline height SDS and baseline IGF-1 SDS, with a sensitivity model adding rhGH dose and Bonferroni correction. Results Of 224 eligible children, 169 with complete baseline and 3-month data formed the primary analysis set, and 210 with 6-month data were analyzed for the 6-month outcome. Baseline fasting insulin correlated with the 3-month change in height SDS [Spearman correlation coefficient (rs) = 0.667], the 3-month height gain (rs = 0.331) and the 6-month change in height SDS (rs = 0.500), all p < 0.0001 and significant after Bonferroni correction. In multivariable regression (coefficient of determination R 2 = 0.209), each 1 μ U/mL higher fasting insulin was associated with a 0.034 greater 3-month change in height SDS (95% confidence interval [CI] 0.018–0.050, p < 0.0001), and the association persisted after adjustment for rhGH dose (0.036, 95% CI 0.020–0.052). Conclusions Baseline fasting insulin was associated with early height SDS gain during rhGH therapy in children with ISS after adjustment for age, sex, baseline height SDS and IGF-1 SDS, although residual confounding, particularly by pubertal status, cannot be excluded. These retrospective, unvalidated findings are hypothesis-generating and do not support using fasting insulin to guide rhGH dosing.

Authors

Institutions

Publication Details

Journal
Frontiers in Pediatrics
Published
2026-11-16
DOI
https://doi.org/10.3389/fped.2026.1951143
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature

Wei Song, Dingding Wang, Yuanyuan Ju
3 links
Frontiers in Pediatrics
Growth Hormone and Insulin-like Growth Factors
article

Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature

Wei Song, Dingding Wang, Yuanyuan Ju
article en

Abstract

Background Fasting insulin modulates growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) synthesis, but its relation to early height response to recombinant human GH (rhGH) therapy is unclear. We examined this in children with idiopathic short stature (ISS). Methods This single-center retrospective cohort study reviewed records of children aged 3–14 years who started rhGH monotherapy for ISS at a tertiary pediatric endocrinology center between December 2018 and December 2024. Children with another identifiable cause of short stature, obesity, diabetes, uncontrolled hypothyroidism, Turner syndrome or concurrent gonadotropin-releasing hormone agonist therapy were excluded. The primary outcome was the change in height standard deviation score (SDS) from baseline to 3 months, and the secondary outcomes were the 3-month height gain and the change in height SDS from baseline to 6 months. Baseline fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) were related to the outcomes by Spearman correlation and by linear regression adjusted for age, sex, baseline height SDS and baseline IGF-1 SDS, with a sensitivity model adding rhGH dose and Bonferroni correction. Results Of 224 eligible children, 169 with complete baseline and 3-month data formed the primary analysis set, and 210 with 6-month data were analyzed for the 6-month outcome. Baseline fasting insulin correlated with the 3-month change in height SDS [Spearman correlation coefficient (rs) = 0.667], the 3-month height gain (rs = 0.331) and the 6-month change in height SDS (rs = 0.500), all p < 0.0001 and significant after Bonferroni correction. In multivariable regression (coefficient of determination R 2 = 0.209), each 1 μ U/mL higher fasting insulin was associated with a 0.034 greater 3-month change in height SDS (95% confidence interval [CI] 0.018–0.050, p < 0.0001), and the association persisted after adjustment for rhGH dose (0.036, 95% CI 0.020–0.052). Conclusions Baseline fasting insulin was associated with early height SDS gain during rhGH therapy in children with ISS after adjustment for age, sex, baseline height SDS and IGF-1 SDS, although residual confounding, particularly by pubertal status, cannot be excluded. These retrospective, unvalidated findings are hypothesis-generating and do not support using fasting insulin to guide rhGH dosing.

Frontiers in PediatricsVol. 14
Second Hospital of Shandong University (CN), Qilu Hospital of Shandong University (CN)
Natural Science Foundation of Shandong Province
Good health and well-being
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon